Trial: 202012053

A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

Phase

III (Cancer Control)

Principal Investigator

Adkins, Douglas

Disease Site

Larynx; Lip, Oral Cavity and Pharynx

Learn more about this study at: clinicaltrials.gov